Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 2 · 1931–2026
Showing the 50 most relevant studies, sorted by most relevant.
Lan Zhang, Min Zhang, Yaping Liu, et al.
Food Bioscience, 2023
Ahmed Hamdi Hattab, Nashwan Omar Tapabashi, Najla Jalil Khalil
2023
Abstract Graphene oxide is a complex substance that possesses significant implications in both theoretical and practical domains. In order to examine the potential of graphene oxide (GO) in reducing the high band gap of conducting materials, the electronic properties, including topography and band gap, the materials were assessed utilising density functional theory (DFT). calculations. The “B3LYP” technique was employed, along with the “6-31G” (d, p) and “LanL2DZ” basis sets. The quantum chemical parameters that have been calculated and found to be connected with reduced efficiency include total energy (E), highest occupied molecular orbital energy (EHOMO), lowest unoccupied molecular orbital energy (ELUMO), energy gap (EH−L), hardness (η), softness (S), and global electrophilicity index (ω). Applying the abbreviated Fukui function and abbreviated softness indicators facilitated the evaluation of potential regions for local reactivity. The results show that the total energy E is the highest at GO/ZnO composite which mean that it the most stable compound. While the EH−L for the composite was about 1.62 and this can prove the evidence that the composite is more relabel for the photo degradation than the ZnO in visible light.
Abstract licence: CC BY 4.0
Travis Tasker, Charles A. Cravotta, Benjamin Roman
2026
N.K. Zhumadillaev
Sheep, goats, wool business, 2024
The researches were carried out on sheep of the Kazakh Kurdy semi-coarse wool breed: rams of producers of the Bayyssk type of the same breed were used on uteruses of the Kargali inbreed type. The level and dynamics of live weight for the suckling period and up to 16 (yarki) months of age, as well as slaughter and meat qualities of rams of 2 and 4 months of age were studied in the obtained offspring. The level of live weight for all the studied age periods was the highest in the young stock obtained from crossing of Kargali inbred type mothers with rams of Bayys type producers, the superiority amounted to 6.0-3.9% at birth (rams - yarochki), 4.3-3.3% at weaning and 2.7% at 16 months of age (yarki). The study of features of articles of physique of 4 and 16 months old yaks showed that in these age periods yarks with genotype KPG-B × KPG-K have an advantage over purebred Kargalinsky coevals KPG-K by all measures of physique. In terms of slaughter indices, KPG-B × KPG-K lambs had superiority over purebred Kargala lambs at both age periods of slaughter
Abstract licence: CC BY
NanoWorld Journal, 2026
V.A. Pogodayev
Sheep, goats, wool business, 2023
U.Sh. Dzhuraeva
Sheep, goats, wool business, 2025
N.K. ZHUMADILLAYEV
Sheep, goats, wool business, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.